Valeritas Announces Participation on “The Cutting Edge of Cannabinoid Science” Panel at the CBD Expo EAST Conference
26 Septembre 2019 - 3:31PM
Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology
company and maker of the V-Go® Wearable Insulin Delivery device,
which uses its proprietary h-Patch™ technology, announced today
that Dr. Jessica Barnes, consultant to the company, will be a
panelist at CBD Expo EAST 2019 being held November 15-16, 2019, at
the Hilton Orlando in Orlando, Florida.
Saturday, November 16,
20192:30 PM ETTitle: The
Cutting Edge of Cannabinoid Science
Abstract: Science has transformed
the world of cannabinoids. CBD was once a relatively obscure,
banned substance. But scientific research landed this compound in
the hands of physicians, engineers, lawmakers, and consumers. In
fact, research fuels innovation. Designers rely on emerging
scientific evidence to develop cannabinoid products that meet the
needs of an evolving market. Where is the science of CBD today? The
past year’s breakthroughs in CBD research include medication
interactions, epilepsy, neuroscience, dermatological applications,
mental health disorders, addiction/relapse, and biochemistry. This
council of established scientists will push your company to the
cutting edge of chemical/medical advancement in the field. Critics
often point out that CBD claims are ahead of the science. But
knowledge is power.
On July 30th, Valeritas announced positive results
from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD)
subcutaneous infusion with two dosing regimens delivered via its
proprietary h-Patch™ wearable drug delivery device. The
company believes this study represents the first report of CBD
delivered via subcutaneous infusion in any preclinical model.
Valeritas’ h-Patch™ is a drug delivery technology
that can facilitate the simple and effective subcutaneous delivery
of injectable medicines to patients across a broad range of
therapeutic areas. The company’s V-Go is the first FDA-approved
product that utilizes the h-Patch™ technology. To date, more
than 20 million V-Go insulin delivery devices have been sold in the
United States.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology
company focused on improving health and simplifying life for people
with diabetes by developing and commercializing innovative
technologies. Valeritas’ flagship product, V-Go® Wearable Insulin
Delivery device, is a simple, affordable, all-in-one basal-bolus
insulin delivery option for patients with type 2 diabetes that is
worn like a patch and can eliminate the need for taking multiple
daily shots. V-Go administers a continuous preset basal rate of
insulin over 24 hours, and it provides discreet on-demand bolus
dosing at mealtimes. It is the only basal-bolus insulin
delivery device on the market today specifically designed keeping
in mind the needs of type 2 diabetes patients. Headquartered in
Bridgewater, New Jersey, Valeritas operates its R&D functions
in Marlborough, Massachusetts.
More information is available
at www.valeritas.com and our Twitter feed
@Valeritas_US, twitter.com/Valeritas_US.
Forward-Looking Statements
This press release may contain forward-looking
statements. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, references to Valeritas
technologies, business and product development plans and market
information. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. Such
factors include, among others: the ability to raise the additional
funding needed to continue to pursue Valeritas’ business and
product development plans; Valeritas' expected cash burn rate and
its ability to continue to increase new and total prescription
growth; the effects of the reverse stock split on the trading price
of Valeritas’ common stock, in both the short and long-term; the
ability to continue to commercialize the V-Go® Wearable Insulin
Delivery device with limited resources; competition in the industry
in which Valeritas operates and overall market conditions; the
inherent uncertainties associated with developing new products or
technologies; the potential commercial use of the h-Patch™
technology for subcutaneous delivery of Apo or CBD is dependent on
Valeritas’ ability to identify one or more potential collaboration
partners and enter into mutually agreeable collaboration agreements
(neither the delivery of Apo or CBD by h-Patch™ is currently
cleared for use by the FDA); our statements that (i) subcutaneous
Apo infusions appears to offer qualitatively comparable benefits to
that of oral levodopa and (ii) based on initial studies,
subcutaneous infusion of CBD appears to offer several distinct
advantages over oral dosing of CBD, and other potential benefits of
the h-Patch™ technology to deliver Apo or CBD is based on
third-party clinical studies not conducted by Valeritas; however,
additional studies or research may be needed by our potential
partners to demonstrate to the U.S. Food and Drug Administration
(“FDA”) that delivery of Apo or CBD via the h-Patch™ technology
will offer consistent results to the initial Valeritas study; and
the FDA or other regulatory agencies may require
Valeritas’ collaboration partners to demonstrate the safety or
effectiveness of subcutaneous infusion of Apo or CBD through the
h-Patch™ technology before either of those products can be
commercialized, which can be a lengthy, and uncertain process.
Statements or claims made by third parties regarding the efficacy
or functionality of V-Go as compared to other products are
statements made by such individual and should not be taken as
evidence of clinical trial results supporting such statements or
claims. Any forward-looking statements are made as of the date of
this press release, and Valeritas assumes no obligation to update
the forward-looking statements or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law. Investors should
consult all of the information set forth herein and should also
refer to the risk factor disclosure set forth in the reports and
other documents Valeritas files with the SEC available at
www.sec.gov.
Investor Contacts:Lynn Pieper Lewis or Greg
ChodaczekGilmartin Group646-924-1769ir@valeritas.com
Media Contact:Kevin KnightKnight Marketing
Communications, Ltd.206-451-4823pr@valeritas.com
Valeritas (NASDAQ:VLRX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Valeritas (NASDAQ:VLRX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025